Clinical Trial Update: Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma [Phase 2]

View source ↗

Summary

This trial update notes that a Phase 2 study of nimotuzumab plus nab-paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma has been withdrawn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Zhejiang University | Conditions: Stage IV Esophageal Squamous Cell Carcinoma | Phase 2 | Status: WITHDRAWN